The co-founder of Legend Biotech—Johnson & Johnson’s partner for the freshly FDA-approved CAR-T therapy Carvykti—has stepped down unexpectedly as its chief scientific officer. Frank Fan, M.D ...

After its mega $424 million IPO this summer, blood cancer focused Legend Biotech is making a big ... reasons,” with Genscript CEO Dr. Frank Zhang swooping in immediately to fill up the vacant ...

Just a month after taking up the CEO role at Legend Biotech, Frank Zhang has been forced to step aside by the board following an investigation into suspected illegal activity by Chinese customs.

On August 1, 2020, the Board of Directors of Legend Biotech appointed Dr. Frank Zhang to serve as Chief Executive Officer, succeeding Dr. Yuan Xu upon her resignation.

Legend Biotech has managed to remove GenScript Biotech ... a position that has been held since 2022 by Frank Zhang, Ph.D., founder of both GenScript and Legend. Thanks to this discretionary ...

Two months of “residential surveillance” have now been turned into an official arrest for Fangliang “Frank” Zhang ... giant Genscript Biotech and its CAR-T subsidiary Legend Biotech.

As biotech has gone from strength to strength ... But companies can also see quickly if their treatment is effective.” Frank Zhang, Legend’s chief executive, says faster trials have aided ...

Zhang is also chairman and chief executive officer of Genscript's unit Legend Biotech Corp LEGN.O. Legend Biotech has appointed its Chief Financial Officer Ying Huang as interim CEO, the Hong Kong ...

Dr. Zhang remains Chairman of the Board of Directors of Legend Biotech. On September 17, 2020, Legend Biotech learned that the Customs Anti-Smuggling Department (the “Authority”) of the People ...